The First Trust NYSE Arca Biotechnology Index Fund (FBT) has experienced a significant inflow of approximately $441.5 million, marking a 16.0% increase in outstanding units from 11,250,002 to 13,050,002 within the past week. This notable shift highlights growing investor interest in biotechnology ETFs.
As of the latest trade, FBT is priced at $248.68, situated between a 52-week low of $158.92 and a high of $258.195. Notable underlying components driving performance include Corcept Therapeutics Inc (CORT), up 3.9%, Veracyte Inc (VCYT), rising 3.2%, and NeoGenomics Inc (NEO), which increased by 2.5%.
This increase in units suggests heightened demand for the underlying assets within FBT’s portfolio, potentially influencing market activity among its constituent stocks.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
